{
  "pmcid": "4281164",
  "sha256": "4cf92206066da3065e018dd2cdb0059c18ec4238a2196aeee387a355a30a7b6e",
  "timestamp_utc": "2025-11-09T22:41:55.829175+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.89480562200957,
    "reading_ease": 18.709576854067024,
    "word_count": 209
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Single-Dose vs. Divided-Dose rATG Induction in Renal Transplantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised, unblinded 2Ã—2 factorial trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "180 adult renal transplant recipients"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either SD-rATG (6 mg/kg over 24 hours) or DD-rATG (four 1.5 mg/kg doses on alternate days)"
      },
      "Objective": {
        "score": 1,
        "evidence": "evaluated the long-term safety and efficacy of single-dose (SD) versus divided-dose (DD) rabbit antithymocyte globulin (rATG) induction in renal transplant recipients"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was renal function, measured by the abbreviated modification of diet in renal disease formula, over a follow-up period averaging 51.8 months"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was computer-generated, and allocation was not concealed"
      },
      "Blinding": {
        "score": 3,
        "evidence": "unblinded"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "90 participants were randomised to each group"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "SD-rATG was associated with improved renal function in deceased donor recipients (P <0.001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the DD group, with higher infection rates"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00906204"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}